Pediatric Epilepsies
Conditions
Keywords
Pediatric Epilepsies, Epilepsies, Pediatric Neuropsychiatry
Brief summary
Epilepsy is one of the most common neurological diseases in Italy, affecting about 500,000 people. Pediatric age represents one of the most affected groups with a consequent significant impact on the quality of life of the families involved. The study aims to monitor the cognitive functions of patients followed at our center in order to determine the main types of pathways and highlight their determinants. The ultimate goal is to define what are the main clinical and instrumental predictors of cognitive function and its variation over time.
Interventions
None listed
Sponsors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* Patients seen at the Children's Neuropsychiatry of the Fondazione Policlinico Gemelli IRCCS (UOS Diagnosis and Treatment of Drug-Resistant Epilepsies, Day Hospital or inpatient setting at the Department of Children's Neuropsychiatry) with onset of first seizure between the ages of 0 and 18 years and subsequent diagnostic confirmation of epilepsy (2 or more unprovoked seizures at least 24 hours apart or definite epilepsy syndrome, with diagnostic confirmation by the child neuropsychiatrist). * Patients already followed at Child Neuropsychiatry with a diagnosis of epilepsy with age of onset between 0 and 18 years. * Patients referred to our Center during follow-up with a diagnosis of epilepsy with age of onset between 0 and 18 years.
Exclusion criteria
* Patients with unconfirmed diagnosis of epilepsy after the first critical episode. * Patients from other Centers, for whom the history, clinical and instrumental data are not sufficiently detailed and in accordance with the methodologies followed at our Center. * Patients with follow-up \< 2 years. * Patients for whom study consent is not provided.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| neurodevelopment level | 12 months after entry visit | Evaluate prescholar global development and scholar cognitive level with Griffiths or Weschler scales where applicable according to age. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Seizure outcome | 24 months after entry visit | Evaluate the reduction in seizures (percentage) |
| QOLIE-31 | 24 months after entry visit | Evaluate the Impact of the Epilepsy on the quality of life |
| Clinical Global Impression Scale | 24 months after entry visit | Evaluate the global clinical impression to have a measure of epilepsy severity and the burden of antiseizure medication on daily life. |
Countries
Italy
Contacts
CONTACTDomenica Immacolata Battaglia, MD
CONTACTMichela Quintiliani, MD
PRINCIPAL_INVESTIGATORDomenica Immacolata Battaglia
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Outcome results
None listed